Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N. Sternberg, Johann S. de Bono, Daniel Castellano, Bertrand Tombal, Christian Wülfing, Michael Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Stéphane Oudard, Gaetano Facchini, Elizabeth M. Poole, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Samira Bensfia, Ronald de Wit
Topics & Concepts
CabazitaxelEnzalutamideMedicineProstate cancerDocetaxelOncologyInternal medicineClinical endpointPopulationAndrogen deprivation therapyAbiraterone acetateQuality of life (healthcare)Progression-free survivalClinical trialCancerAndrogen receptorChemotherapyEnvironmental healthNursingProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments